Vector Center is developing an mRNA coronavirus vaccine – expert

0

NOVOSIBIRSK. KAZINFORM – The Russian State Research Center for Virology and Biotechnology is developing an mRNA coronavirus vaccine, Yelena Nechayeva, the center’s deputy director general, said on Wednesday, TASS reports.

“There are no mRNA vaccines in Russia, but now several organizations, including Vector, are working on it,” she told TASS on the sidelines of the Openbio forum.

According to Nechayeva, the center is currently working on technologies and control methods for vaccine development. Preclinical tests have not yet started.

She noted that the development of mRNA vaccines is a promising area around the world. These vaccines should be safer and cheaper than existing vaccines. In addition, their production will take less time.

However, in his words, there are currently problems with the supply of raw materials. “We are going to substitute something, other things, for example ferments, will be produced locally. Russian developers keep up with the times, with world science. I think Russian mRNA vaccines will be in high demand,” she said.

Gamaleya Center Deputy Director General Denis Logunov said earlier that his center was also developing an mRNA vaccine against the coronavirus. A special laboratory group has been set up at the center, and the results of the experiments demonstrate a high rate of expression. According to Loginov, unlike vector vaccines, which can only be used once every six months, mRNA vaccines have no such limitations.

mRNA vaccines use a copy of a molecule called messenger RNA (mRNA) to trigger an immune response. RNA-based vaccines encode a pathogen protein. Along with RNA, these vaccines have lipid membranes that prevent RNA from degrading and allow RNA to enter the cell. When a vaccine RNA enters the cell, the cell’s protein synthesis mechanisms produce an RNA-encoded protein, which acts as an antigen: it is detected by the immune system and teaches it to develop immunity.

Photo: images.theconversation.com

Share.

About Author

Comments are closed.